Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review-Reference-Cited by-同舟云学术

Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review

Published:2016-12-16 Issue:1 Volume:42 Page:75-79
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Jancel T.¹,Shaw P. A.²,Hallahan C. W.³,Kim T.⁴,Freeman A. F.⁵,Holland S. M.⁵,Penzak S. R.⁶

Affiliation:

1. Office of Surveillance and Epidemiology; U.S. Food and Drug Administration; Silver Spring MD USA

2. Department of Biostatistics and Epidemiology; University of Pennsylvania Perelman School of Medicine; Philadelphia PA USA

3. Biostatistics Research Branch; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda MD USA

4. Clinical Center Pharmacy Department; National Institutes of Health; Bethesda MD USA

5. Laboratory of Clinical Infectious Diseases; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda MD USA

6. Department of Pharmacotherapy; University of North Texas System College of Pharmacy; Fort Worth TX USA

Funder

Division of Intramural Research

National Institute of Allergy and Infectious Diseases

National Institutes of Health

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcpt.12483/fullpdf

Reference25 articles.

1. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts;Sabatelli;Antimicrob Agents Chemother,2006

2. Noxafil (posaconazole) [package insert] Whitehouse Station, NJ Merck & Co., Inc. 2015

3. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension;Krishna;Antimicrob Agents Chemother,2012

4. Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis;Dolton;Antimicrob Agents Chemother,2014

5. Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers;Dodds Ashley;Antimicrob Agents Chemother,2009

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of Liquisolid Pellets Technology for Improving Dissolution of Posaconazole: A DoE Based Process Optimization;Journal of Pharmaceutical Innovation;2024-04-24

2. General Management of the Patient: Specific Aspects of Infectious Disease Supportive Care in Children;The EBMT Handbook;2024

3. New and emerging options for management of invasive fungal diseases in paediatric patients;Mycoses;2023-10-04

4. Population pharmacokinetics of posaconazole in Chinese pediatric patients with acute leukaemia: Effect of food on bioavailability and dose optimization;European Journal of Pharmaceutical Sciences;2022-11

5. A Review of Population Pharmacokinetic Models of Posaconazole;Drug Design, Development and Therapy;2022-10